Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643546 | 1.00 | LMNA (0.41) | LMNAMEN1KMT2ANR1H4GPR183 | |
| SCHEMBL2644272 | 0.85 | MEN1 (0.41) | LMNAMEN1KMT2ANR1H4GPR183 | |
| SCHEMBL2644270 | 0.85 | MEN1 (0.41) | LMNAMEN1KMT2ANR1H4GPR183 | |
| SCHEMBL2644740 | 0.84 | GCGR (0.41) | LMNAMEN1KMT2ANR1H4 | |
| SCHEMBL2644741 | 0.84 | GCGR (0.41) | LMNAMEN1KMT2ANR1H4 | |
| SCHEMBL2644291 | 0.79 | GCGR (0.44) | LMNAMEN1KMT2A | |
| SCHEMBL2644287 | 0.79 | GCGR (0.44) | LMNAMEN1KMT2A | |
| SCHEMBL2643340 | 0.75 | GCGR (0.46) | NR1H4 | |
| SCHEMBL2643338 | 0.75 | GCGR (0.46) | NR1H4 | |
| SCHEMBL2656108 | 0.73 | FFAR2 (0.38) | MEN1KMT2ANR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116483-A1 | Glucagon antagonists/inverse agonists | BEHRENS CARSTEN (DK) | 2004-06-17 | — | — | US | disclosed |
| US-6649641-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187982-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LMNA 3715/4885MEN1 2605/4885KMT2A 3268/4885 |
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LMNA 3715/4885MEN1 2605/4885KMT2A 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.